Finance

Lists
P8A:SGX
Cordlife Group Ltd
SGD 0.13
0.00%
(0.00) 1D
Aug 21, 1:25:58 PM GMT+8  ·   SGD
All symbols
SymbolPriceChange% Change
Generating top insights for P8A...
Mkt. cap
35.31M
Avg. vol.
7.39K
Volume
0.00
52-wk high
SGD 0.26
52-wk low
SGD 0.10
EPS
-SGD 0.04
Shares outstanding
267.53M
No. of employees
111
Mkt. cap
35.31M
Avg. vol.
7.39K
Volume
0.00
52-wk high
SGD 0.26
52-wk low
SGD 0.10
EPS
-SGD 0.04
Shares outstanding
267.53M
No. of employees
111
Profile
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012. Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services. Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn. In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
About Cordlife Group Ltd
CEOYiu Pang Fai
Employees111
FoundedMay 2, 2001
Headquarters-
SectorHealth care provider
Previous reportsAll values in SGD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SGD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
10.21M
9.46M
8.99M
8.30M
Cost of goods sold
4.16M
4.05M
3.78M
3.44M
Cost of revenue
4.16M
4.05M
3.78M
3.44M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.42M
10.52M
7.60M
6.41M
Operating expense
9.29M
10.41M
7.47M
6.36M
Total operating expenses
13.45M
14.46M
11.25M
9.80M
Operating income
-3.24M
-5.00M
-2.26M
-1.50M
Other non operating income
-
-
-
-
EBT including unusual items
-2.33M
-4.30M
-1.70M
-873.00K
EBT excluding unusual items
-2.33M
-4.38M
-1.70M
-873.00K
Income tax expense
149.00K
1.26M
19.00K
64.00K
Effective tax rate
-6.39%
-29.22%
-1.12%
-7.33%
Other operating expenses
-133.00K
-111.00K
-132.00K
-54.00K
Net income
-2.48M
-5.55M
-1.72M
-936.00K
Net profit margin
-24.32%
-58.72%
-19.13%
-11.28%
Earnings per share
-
-
-
-
Interest and investment income
642.00K
589.00K
565.00K
587.00K
Interest expense
-27.00K
-34.00K
-28.00K
-77.00K
Net interest expenses
615.00K
555.00K
537.00K
510.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.17M
-4.29M
-1.33M
-621.00K
Gain or loss from assets sale
1.00K
220.00K
5.00K
4.00K
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps